We observed an increased frequency of TIM-3–expressing NK cells in early posttransplant AML patients, consistent with other studies reporting that high TIM-3 expression on NK cells from AML patients correlates with an enhanced NK cell cytotoxicity and effector functions and an ultimately improved clinical outcome in AML patients (57). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.